on-01910 and Sepsis

on-01910 has been researched along with Sepsis* in 1 studies

Other Studies

1 other study(ies) available for on-01910 and Sepsis

Article	Year
Rigosertib inhibits MEK1-ERK pathway and alleviates lipopolysaccharide-induced sepsis. Immunity, inflammation and disease, 2021, Volume: 9, Issue:3 Here, by using the lipopolysaccharide (LPS)-induced mice sepsis model, we treated septic wild-type (WT) mice or MEK1. We also generated macrophages derived from bone marrow from WT or MEK1. Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha [TNF-α] and interleukin-6 [IL-6], and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-α and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1 Topics: Animals; Glycine; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Sepsis; Sulfones	2021

Article

Year

Rigosertib inhibits MEK1-ERK pathway and alleviates lipopolysaccharide-induced sepsis.

Immunity, inflammation and disease, 2021, Volume: 9, Issue:3

Here, by using the lipopolysaccharide (LPS)-induced mice sepsis model, we treated septic wild-type (WT) mice or MEK1. We also generated macrophages derived from bone marrow from WT or MEK1. Rigosertib suppressed LPS or poly I:C-induced expression of inflammatory cytokines (tumor necrosis factor-alpha [TNF-α] and interleukin-6 [IL-6], and IL-23) in WT bone marrow-derived macrophages while failed to affect the upregulation of TNF-α and IL-6 in LPS-treated bone marrow-derived macrophages from MEK1

Topics: Animals; Glycine; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Sepsis; Sulfones

2021